Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TDO2 | P48775 | 1/20 | 0.57 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179190 | 0.94 | IDO1 (0.64) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL29935305 | 0.94 | IDO1 (0.64) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL20805555 | 0.91 | IDO1 (0.48) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL179169 | 0.91 | IDO1 (0.57) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL20198886 | 0.89 | IDO1 (0.50) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL179217 | 0.89 | IDO1 (0.56) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL23236569 | 0.88 | IDO1 (0.70) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL144580 | 0.88 | IDO1 (0.63) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL144581 | 0.88 | IDO1 (0.63) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL21538730 | 0.87 | IDO1 (0.53) | IDO1CYP3A4CYP2C9TDO2IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348289-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2017-12-07 | — | — | US | disclosed |
| US-9789094-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE HOLDINGS CORPORATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160220543-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2016-08-04 | — | — | US | disclosed |
| US-9320732-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150352206-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150190378-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION (US) | 2015-07-09 | — | — | US | disclosed |
| US-8993605-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140315962-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION (US) | 2014-10-23 | — | — | US | disclosed |
| US-8822511-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8796319-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION (US) | 2014-01-23 | — | — | US | disclosed |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315962-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-20170348289-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-20150352206-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | ICOS, CD274, IDO1 | IDO1 3/4885CYP3A4 2311/4885CYP2C9 4210/4885 |
| US-20150190378-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-20160220543-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 131/4885CYP2C9 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.